ReFlow Medical recalls lots of its Wingman35 Crossing Catheters

ReFlow Medical voluntarily recalled certain lots of its Wingman35 Crossing Catheters, which are used in the peripheral vasculature.

The company announced the recall May 3 after discovering the catheters exhibited tip splitting or separation, which resulted in two adverse events.

The FDA deemed the action a class 1 recall, which the agency defines as “a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.”

The recalled products were distributed between January 2015 and March 2016. ReFlow Medical said that 2,327 Wingman catheters are in distribution.

According to the company, tip splitting could lead to loss of device function and tip separation could require medical intervention or occlude blood flow to end organs.

In October 2014, the FDA granted a 510(k) clearance to the Wingman35 Crossing Catheters, which are used with steerable guidewires to access discrete regions of the peripheral vasculature and enable lesion crossing.

Tim Casey,

Executive Editor

Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.